Literature DB >> 24625552

Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations.

S Matarraz1, B Paiva2, M Díez-Campelo3, S Bárrena1, M Jara-Acevedo1, M L Gutiérrez1, J M Sayagués1, M-L Sánchez1, P Bárcena1, M P Garrastazul4, M J Berruezo4, J M Duran5, C Cerveró6, J A García-Erce7, L Florensa8, G D Méndez9, O Gutierrez10, M C Del Cañizo3, J J M van Dongen11, J F San Miguel2, A Orfao1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24625552     DOI： 10.1038/leu.2014.103

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.

Authors:  T M Westers; R Ireland; W Kern; C Alhan; J S Balleisen; P Bettelheim; K Burbury; M Cullen; J A Cutler; M G Della Porta; A M Dräger; J Feuillard; P Font; U Germing; D Haase; U Johansson; S Kordasti; M R Loken; L Malcovati; J G te Marvelde; S Matarraz; T Milne; B Moshaver; G J Mufti; K Ogata; A Orfao; A Porwit; K Psarra; S J Richards; D Subirá; V Tindell; T Vallespi; P Valent; V H J van der Velden; T M de Witte; D A Wells; F Zettl; M C Béné; A A van de Loosdrecht
Journal:  Leukemia       Date:  2012-02-06       Impact factor: 11.528

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

3.  Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Authors:  S Z Usmani; J Crowley; A Hoering; A Mitchell; S Waheed; B Nair; Y AlSayed; F Vanrhee; B Barlogie
Journal:  Leukemia       Date:  2012-06-18       Impact factor: 11.528

4.  Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

Authors:  Saad Z Usmani; Rachel Sexton; Antje Hoering; Christoph J Heuck; Bijay Nair; Sarah Waheed; Yazan Al Sayed; Nabeel Chauhan; Nisar Ahmad; Shebli Atrash; Nathan Petty; Frits van Rhee; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2012-06-06       Impact factor: 22.113

5.  Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients.

Authors:  L E Roeker; D R Larson; R A Kyle; S Kumar; A Dispenzieri; S V Rajkumar
Journal:  Leukemia       Date:  2013-02-05       Impact factor: 11.528

6.  Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.

Authors:  Bart Barlogie; Guido Tricot; Jeff Haessler; Frits van Rhee; Michele Cottler-Fox; Elias Anaissie; James Waldron; Mauricio Pineda-Roman; Raymond Thertulien; Maurizio Zangari; Klaus Hollmig; Abid Mohiuddin; Yazan Alsayed; Antje Hoering; John Crowley; Jeffrey Sawyer
Journal:  Blood       Date:  2007-09-25       Impact factor: 22.113

7.  Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.

Authors:  Saad Z Usmani; Jeffrey Sawyer; Adam Rosenthal; Michele Cottler-Fox; Joshua Epstein; Shmuel Yaccoby; Rachael Sexton; Antje Hoering; Zeba Singh; Christoph J Heuck; Sarah Waheed; Nabeel Chauhan; Donald Johann; Al-Ola Abdallah; Jameel Muzaffar; Nathan Petty; Clyde Bailey; John Crowley; Frits van Rhee; Bart Barlogie
Journal:  Blood       Date:  2013-04-19       Impact factor: 22.113

Review 8.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

9.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Authors:  Antonio Palumbo; Roman Hajek; Michel Delforge; Martin Kropff; Maria Teresa Petrucci; John Catalano; Heinz Gisslinger; Wiesław Wiktor-Jędrzejczak; Mamia Zodelava; Katja Weisel; Nicola Cascavilla; Genadi Iosava; Michele Cavo; Janusz Kloczko; Joan Bladé; Meral Beksac; Ivan Spicka; Torben Plesner; Joergen Radke; Christian Langer; Dina Ben Yehuda; Alessandro Corso; Lindsay Herbein; Zhinuan Yu; Jay Mei; Christian Jacques; Meletios A Dimopoulos
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

10.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245
View more
  4 in total

Review 1.  Second malignancies in multiple myeloma; emerging patterns and future directions.

Authors:  Kylee Maclachlan; Benjamin Diamond; Francesco Maura; Jens Hillengass; Ingemar Turesson; C Ola Landgren; Dickran Kazandjian
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

2.  Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Authors:  Theresia M Westers; Eline M P Cremers; Uta Oelschlaegel; Ulrika Johansson; Peter Bettelheim; Sergio Matarraz; Alberto Orfao; Bijan Moshaver; Lisa Eidenschink Brodersen; Michael R Loken; Denise A Wells; Dolores Subirá; Matthew Cullen; Jeroen G Te Marvelde; Vincent H J van der Velden; Frank W M B Preijers; Sung-Chao Chu; Jean Feuillard; Estelle Guérin; Katherina Psarra; Anna Porwit; Leonie Saft; Robin Ireland; Timothy Milne; Marie C Béné; Birgit I Witte; Matteo G Della Porta; Wolfgang Kern; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

3.  Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.

Authors:  T Matthes; T McKee; I Dunand-Sauthier; B Manfroi; S Park; J Passweg; B Huard
Journal:  Leukemia       Date:  2015-03-10       Impact factor: 11.528

4.  Altered neutrophil immunophenotypes in childhood B‑cell precursor acute lymphoblastic leukemia.

Authors:  Elen Oliveira; Thiago S Bacelar; Juana Ciudad; Maria Cecília M Ribeiro; Daniela R N Garcia; Lukasz Sedek; Simone F Maia; Daniel B Aranha; Indyara C Machado; Arissa Ikeda; Bianca F Baglioli; Nathalia Lopez-Duarte; Lisandra A C Teixeira; Tomasz Szczepanski; Maria Luiza M Silva; Marcelo G P Land; Alberto Orfao; Elaine S Costa
Journal:  Oncotarget       Date:  2016-04-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.